tiprankstipranks

Vivoryon Therapeutics Showcases New Kidney Disease Treatment

Vivoryon Therapeutics Showcases New Kidney Disease Treatment

Vivoryon Therapeutics AG (GB:0R3M) has released an update.

Vivoryon Therapeutics N.V. is set to present its findings on Varoglutamstat, a potential new treatment for Diabetic Kidney Disease, at ASN Kidney Week 2024. The clinical-stage biotechnology company is exploring Varoglutamstat’s ability to increase glomerular filtration in the elderly without proteinuria. Vivoryon, known for its work on small molecule medicines, continues to expand its pipeline with treatments for Alzheimer’s, kidney diseases, cancer, and more.

For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App